Clinical Trial Update: A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nintedanib to placebo in scleroderma-related lung fibrosis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scleroderma
• Scleroderma-related Lung Fibrosis
• Systemic Sclerosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Scleroderma, Systemic | Phase 3 | Status: COMPLETED | Results posted: 2019-12-13